SFI Health™ Celebrates Neurodiversity with Inclusive Global Workplace Initiatives
24.7.2025 08:15:00 CEST | Business Wire | Press Release
SFI Health™ is proud to introduce global comprehensive initiatives to celebrate and support neurodiversity within its workforce. As a global company operating across multiple time zones and cultures, SFI Health™ recognizes that embracing diverse ways of thinking is essential to drive innovation, enhance employee wellbeing, and deliver superior value to customers worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250723850754/en/
"Every mind matters, Every action helps": SFI Health™ celebrates Neurodiversity to promote a “thinking-differently” community
Specifically, the 2025 edition of these initiatives, titled “Every mind matters, Every action helps”, aims to foster a more inclusive, innovative, and supportive work environment for all team members, recognizing the unique strengths and perspectives that neurodiverse and neurotypical individuals bring to the organization.
As part of this commitment, the SFI Health EMEA, the regional office of SFI Health™, has arranged a series of programs and resources, which all team members are encouraged to engage with and contribute to further strengthen inclusivity:
- Webinar “A Celebration of Neurodiversity at SFI Health: Every Mind Matters, Every Action Helps.” hosted by Dr. Tony Lloyd, an internationally renowned consultant and trainer, specialising in neurodiversity. This educational session, addressed to employees, as well as open to commercial distributors, aims to deepen understanding of neurodiversity, and to help acknowledge the benefits from neuro-inclusion to build a stronger and more connected business community. Specifically, this could mean reshaping recruitment, onboarding and assessment processes by adopting a strength-based approach.
- Virtual Awareness Session – “Understanding Neurodiversity: ADHD, Autism & Sensory Sensitivities”. This session provides an overview of ADHD and autism, their overlapping traits, lesser-known metabolic aspects of autism, and their impact on sensory challenges and workplace coping strategies. The event will also feature a personal testimonial from a person diagnosed as autistic after the age of 20, offering insights to promote better understanding, empathy, and support for a more inclusive work environment.
- Employees Workshop: This collaborative workshop focuses on enhancing internal teamwork among colleagues: employees have been invited to share their thinking style, their approaches to problem-solving and communication, fostering greater mutual understanding and effective collaboration.
Following these events, a company-wide survey will be conducted to evaluate learning outcomes and assess employees’ confidence in applying neurodiversity principles in their day-to-day work. The insights gathered will inform future initiatives, helping embed neuro-inclusion as a foundational pillar of SFI Health™’s culture.
“Neurodiversity refers to the natural variation in human brains and minds,” said Dr. Tony Lloyd, consultant, psychotherapist, coach & neurodiversity specialist. “Far from being a limitation, these differences have an evolutionary purpose and represent unique strengths — from creative problem-solving and pattern recognition to hyperfocus and analytical thinking — which can fuel innovation and competitive advantage.”
“Research shows that diverse workforces are linked to greater profitability and enhanced wellbeing,” commented Matthew Brabazon, General Manager at SFI Health™ EMEA. “At SFI Health™, this initiative aligns with our core values of promote diversity, respect, empathy, and continuous learning. By embracing ‘thinking differently’, we aim to unlock new ideas that serve our customers better and foster a culture where all employees feel valued.”
About SFI Health™
SFI Health™ is a global leader in natural healthcare, specialized in the design, development and commercialization of clinically researched products in the areas of microbiome, cognition and wellbeing.
Guided by the belief in the healing potential of natural products, SFI Health™ combines a rigorous pharma-based approach with the benefits of naturally sourced solutions.
An extensive network of trusted business partners enables the company, headquartered in Australia, to market its own brands, reaching consumers in over 50 countries. The EMEA SFI Health™ regional office in Lugano, Switzerland, manages commercial operations across Europe, Middle East and Africa.
SFI Health™ is committed to fostering confidence in natural healthcare by sharing state-of-the-art research, technical expertise and comprehensive sales & marketing resources with consumers, healthcare professionals and partners worldwide.
For more information go to sfihealth.com or follow us SFI Health on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250723850754/en/
Contacts
For more information
SFI Health™ EMEA Contact
Elisabetta Bianchi
e-mail address: elisabetta.bianchi@sfihealth.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom